Übersetzung für "Generic companies" in Deutsch

Generic companies argued that such delays limit savings for health bodies.

The European Commission has closed its antitrust investigation into generic pharmaceutical companies in France.

For all references to products or companies, generic names must be used .

To this end the Commission selected 43 originator companies and 27 generic companies for in depth analysis.

Nevertheless, such interventions can lead to substantial delays for generic companies when bringing their products on to the market.

However, generic companies and consumer associations sometimes questioned the actual improvement in certain medicines in terms of therapeutic benets.

Generic pharmaceutical companies produce the largest part of the critical hospital medicines that are now urgently needed in large scale volumes to avoid shortages.

The inquiry focused in particular on the practices which originator companies may use to block or delay not only competition by generic companies, but also the development of competing originator products.

The market share (in volume terms) of the generic companies was about 30% at the end of the first year and 45% after two years.

One third of these agreements were concluded with generic companies before the originator company's product lost exclusivity ("early entry agreements").

In the course of the inquiry, the Commission consulted all interested stakeholders, such as originator and generic companies, industry associations, consumer and patients' associations, insurance companies, associations of doctors, pharmacists and hospitals, health authorities, the European Patent Office (EPO), parallel traders, and NCAs.

Industry also expressed interest that any new rules on data protection should keep a fair balance between the interests of research and generic companies.

Options B and C could lead to lower prices for users by increasing the market share of generic companies, but could also imply a lower number of AS on the market and possible resulting costs for users.

The inquiry established that between 2000 and June 2008, more than 200 settlement agreements were concluded between originator and generic companies.

The number of patent litigation cases between originator and generic companies increased by a factor of four between 2000 and 2007.

The objectives of the revision are to further harmonize the authorisation procedure of plant protection products, to define the missions of EFSA for evaluation of active substances and to review the rules on data protection in order to keep a fait balance between the interests of research and generic companies.

But they can extend the examination period of the patent office, as the examination of divisional applications continues even if the parent application is withdrawn or revoked, which, under certain conditions, can add to the legal uncertainty for generic companies.

This is intended to provide an additional incentive to encourage small and medium-sized enterprises, including generic companies, to develop off-patent medicinal products for the paediatric population.

The Commission asked 41 originator and 45 generic companies to submit copies of their patent settlement agreements relevant for the EU/EEA markets, in order to better understand the use of patent settlements in the EU and to help identifying those that might need further scrutiny.

These agreements are very different from other settlements of patent disputes where generic companies are not simply paid off to stay out of the market.

The inquiry dealt with the competitive relationship (i) between originator and generic companies and (ii) amongst originator companies and made important policy recommendations on how to improve the functioning of the sector.

That is intended to provide an additional incentive to attract small and medium sized enterprises, including generic companies, to develop off-patent medicines for children.

A reduced market share of generic companies (under option A) could cause higher costs to PPP users.

In the cases where they opposed, generic companies prevailed in approximately 60% of final decisions rendered by the EPO (including the Boards of Appeal) in the period 2000 to 2007 and the scope of the originator patent was restricted in another 15% of the cases.

In its Statement of Objections, the Commission takes the preliminary view that Lundbeck concluded agreements with generic companies to prevent the market entry of competing generic versions of its best-selling medicine citalopram.

Currently the data protection rules are working against generic competition and the market share of generic companies remains low in most EU countries.

Likewise, generic uptake seems to be faster and ultimately generic prices seem to decrease more in Member States which do not oblige the generic companies to respect a certain price cap (e.g. a fixed percentage of the originator product price).

Industry, most prominently generic companies, complained about the possibilities of originator companies to intervene in regulatory proceedings before marketing authorisation bodies and reported about diverging approaches to the disclosure of confidential information taken by different national authorities.